Compare Neurocrine Biosciences Inc (NBIX) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ross Stores, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Ross Stores, Inc. trades at $225.95 (market cap $73.25B). The key difference: Ross Stores, Inc. is far larger — about 4.6× Neurocrine Biosciences Inc's market cap, and Ross Stores, Inc. pays a 0.78% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | ROST | |
|---|---|---|
Market Cap | $15.77B | $73.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $255.23 |
52-Week Low | $123.10 | $144.67 |
Enterprise Value | $15.78B | $73.70B |
Dividend Yield | — | 0.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Ross Stores (ROST) trades at $229.31, down 0.6% on the day, showing bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.66 beating expectations by 36%. Revenue growth accelerated to 13% in Q2 2026, with comparable store sales surging 10% driven by increased traffic and margin expansion. The stock faces technical resistance near $234 while maintaining strong analyst support with a $271.33 consensus price target.
ROST presents a compelling growth story with robust fundamentals but faces near-term technical headwinds. The company's value-focused retail strategy resonates with cost-conscious consumers, driving consistent earnings outperformance. Key risks include competitive pressures in off-price retail and macroeconomic sensitivity. With 64% of analysts maintaining buy ratings and a 19% upside to consensus targets, the stock offers growth potential for investors comfortable with current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
